"The U.S. Food and Drug Administration today approved Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS).
MS is a chronic, inflammatory, autoimmune disease of the central nervous system"...
- Patient Information:
Details with Side Effects
The most frequently reported serious adverse reactions with Rebif® were psychiatric disorders including depression and suicidal ideation or attempt (see WARNINGS). The incidence of depression of any severity in the Rebif®-treated groups and placebo-treated group was approximately 25%. In post-marketing experience, Rebif® administration has been rarely associated with severe liver dysfunction, including hepatic failure requiring liver transplantation (see WARNINGS: Hepatic Injury).
The most commonly reported adverse reactions were injection site disorders, influenza-like symptoms (headache, fatigue, fever, rigors, chest pain, back pain, myalgia), abdominal pain, depression, elevation of liver enzymes and hematologic abnormalities. The most frequently reported adverse reactions resulting in clinical intervention (e.g., discontinuation of Rebif®, adjustment in dosage, or the need for concomitant medication to treat an adverse reaction symptom) were injection site disorders, influenza-like symptoms, depression and elevation of liver enzymes (see WARNINGS).
In Study 1, 6 patients randomized to Rebif® 44 mcg three times per week (3%), and 2 patients who received Rebif® 22 mcg three times per week (1%) developed injection site necrosis during two years of therapy. Rebif® was continued in 7 patients and interrupted briefly in one patient. There was one report of injection site necrosis in Study 2 during 48 weeks of Rebif® treatment. All events resolved with conservative management; none required skin debridement or grafting.
The rates of adverse reactions and association with Rebif® in patients with relapsing-remitting multiple sclerosis are drawn from the placebo-controlled study (n = 560) and the active comparator-controlled study (n = 339).
The population encompassed an age range from 18 to 55 years. Nearly three-fourths of the patients were female, and more than 90% were Caucasian, largely reflecting the general demographics of the population of patients with multiple sclerosis.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of Rebif® cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice.
Table 3 enumerates adverse events and laboratory abnormalities that occurred at an incidence that was at least 2% more in either Rebif®-treated group than was observed in the placebo group.
Table 3: Adverse Reactions and Laboratory
Abnormalities in Study 1
|Body System Preferred Term||Placebo tiw
|Rebif® 22 mcg tiw
|Rebif® 44 mcg tiw
|BODY AS A WHOLE|
|INJECTION SITE DISORDERS|
|Injection Site Reaction||39%||89%||92%|
|Injection Site Necrosis||0%||1%||3%|
|CENTRAL & PERIPH NERVOUS SYSTEM DISORDERS|
|GASTROINTESTINAL SYSTEM DISORDERS|
|LIVER AND BILIARY SYSTEM DISORDERS|
|Hepatic Function Abnormal||2%||4%||9%|
|MUSCULO-SKELETAL SYSTEM DISORDERS|
|URINARY SYSTEM DISORDERS|
The adverse reactions were generally similar in Studies 1 and 2, taking into account the disparity in study durations.
As with all therapeutic proteins, there is a potential for immunogenicity. In study 1, the presence of neutralizing antibodies (NAb) to Rebif® was determined by collecting and analyzing serum pre-study and at 6 month time intervals during the 2 years of the clinical trial. Serum NAb were detected in 59/189 (31%) and 45/184 (24%) of Rebif®-treated patients at the 22 mcg and 44 mcg three times per week doses, respectively, at one or more times during the study. The clinical significance of the presence of NAb to Rebif® is unknown.
The data reflect the percentage of patients whose test results were considered positive for antibodies to Rebif® using an antiviral cytopathic effect assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of NAb positivity in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications and underlying disease. For these reasons, comparison of the incidence of antibodies to Rebif® with the incidence of antibodies to other products may be misleading.
Drug Abuse And Dependence
There is no evidence that abuse or dependence occurs with Rebif® therapy. However, the risk of dependence has not been systematically evaluated.
Read the Rebif (interferon beta-1a) Side Effects Center for a complete guide to possible side effects
No formal drug interaction studies have been conducted with Rebif®. Due to its potential to cause neutropenia and lymphopenia, proper monitoring of patients is required if Rebif® is given in combination with myelosuppressive agents.
Also, the potential for hepatic injury should be considered when Rebif® is used in combination with other products associated with hepatic injury, or when new agents are added to the regimen of patients already on Rebif® (see WARNINGS: Hepatic injury).
In a nonrandomized prospective clinical study, 86 multiple sclerosis (MS) patients on Rebif® 44 mcg three times per week for at least 6 months and 77 patients not receiving interferon received influenza vaccination. The proportion of patients achieving a positive antibody response (defined as a titer > 1:40 measured by a hemagglutination inhibition assay) was similar in the two groups (93% and 91%, respectively). The exact relationship of antibody titers to vaccine efficacy was not studied and is not known in patients receiving Rebif®. Therefore, while patients receiving Rebif® may receive concomitant vaccination, the overall effectiveness of such vaccination is unknown.
Last reviewed on RxList: 5/3/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Rebif Information
Rebif - User Reviews
Rebif User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.